Todays Report: The 1,513 Shares of Intercept Pharmaceuticals Inc. (ICPT) Stock are sold by David Shapiro

The 1,513 Shares of Intercept Pharmaceuticals Inc. (ICPT) Stock are sold by David Shapiro

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CMO David Shapiro sold 1,513 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $163.08, for a total value of $246,740.04. Following the transaction, the chief marketing officer now owns 46,196 shares of the company’s stock, valued at $7,533,643.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Shapiro also recently made the following trade(s): On Monday, September 26th, David Shapiro sold 3,545 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $165.08, for a total value of $585,208.60.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 153.51 on Friday. The firm’s market cap is $3.80 billion. Intercept Pharmaceuticals Inc. has a 1-year low of $89.76 and a 1-year high of $217.99. The firm has a 50-day moving average price of $158.07 and a 200 day moving average price of $150.46.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.69) by $0.55. The firm earned $5.52 million during the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The company’s quarterly revenue was up 1140.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.99) EPS. Equities analysts predict that Intercept Pharmaceuticals Inc. will post ($16.31) earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in ICPT. CENTRAL TRUST Co bought a new position in shares of Intercept Pharmaceuticals during the second quarter valued at $107,000. Legal & General Group Plc boosted its position in Intercept Pharmaceuticals by 15.8% in the first quarter. Legal & General Group Plc now owns 1,144 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 156 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares during the period. Pacer Advisors Inc. acquired a new position in Intercept Pharmaceuticals during the second quarter worth approximately $180,000. Finally, IBM Retirement Fund boosted its position in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 58 shares during the period. 81.86% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts recently commented on ICPT shares. Wedbush restated an “outperform” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, September 16th. Wells Fargo & Co. restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 28th. Cantor Fitzgerald started coverage on Intercept Pharmaceuticals in a research note on Wednesday, July 6th. They issued a “sell” rating and a $58.00 target price for the company. Robert W. Baird restated an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research note on Thursday, September 22nd. Finally, Morgan Stanley restated a “sell” rating and issued a $80.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, August 5th. Five equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $177.67.

Intercept Pharmaceuticals Company Profile

Related posts

Leave a Comment